AstraZeneca is making a bold move to enhance its oncology research capabilities by bringing AI expertise in-house. The pharmaceutical giant has acquired Boston-based AI company Modella AI to deepen its use of artificial intelligence across its research and clinical development efforts. The goal? To leverage AI to speed up the time-consuming process of drug development, particularly in the field of oncology, which is becoming more complex and data-driven.
The decision to fully integrate Modella’s AI models, data, and staff into AstraZeneca reflects a broader trend in the pharmaceutical industry, where companies are increasingly acquiring AI firms instead of just forming partnerships. This shift gives pharmaceutical companies greater control over how AI is developed, tested, and implemented in highly regulated settings like clinical trials. For AstraZeneca, this acquisition is the next step in a collaboration that began several years ago, during which both parties tested how Modella’s tools could fit into AstraZeneca’s research environment.
Modella AI focuses on using artificial intelligence to analyze pathology data such as biopsy images, linking them to clinical information to uncover patterns. These patterns are vital in discovering biomarkers that could guide treatment choices and improve trial designs. By bringing this technology and expertise in-house, AstraZeneca aims to enhance its capabilities in biomarker discovery and accelerate the development of targeted therapies.
AstraZeneca executives believe that integrating Modella’s AI tools will “supercharge” their efforts in quantitative pathology and make clinical decisions more data-driven. The integration is expected to streamline the trial process, especially when it comes to patient selection. Matching patients to the right trials quickly and accurately can significantly improve trial outcomes and reduce delays that often lead to costly setbacks in drug development.
Moreover, this move highlights how large pharmaceutical companies are reevaluating their approach to AI talent. Rather than relying on external vendors, AstraZeneca is bringing machine learning experts and data scientists directly into its research teams. This shift not only allows the company to have more control over the AI tools but also ensures that AI development aligns closely with its ongoing research needs.
AstraZeneca’s acquisition of Modella marks the first time a major pharmaceutical company has acquired an AI firm outright, setting it apart from other companies in the sector. While many pharmaceutical companies are partnering with AI firms to tap into their capabilities, AstraZeneca is choosing to make a long-term commitment by embedding AI technology directly into its research operations.
This strategic acquisition is part of AstraZeneca’s broader plan for 2026, which includes several important trial results and the goal of reaching $80 billion in annual revenue by 2030. The company hopes that the integration of AI into its drug discovery process will not only streamline research but also help it meet its ambitious growth targets.
